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Introduction 
Motility and migratory capacity are important to 
tumor cells, which maybe tumor cells’ invasion and 
metastasis potential. It will make the malignant cells 
gain the ability to migrate that the rearrangements of 
the actin cytoskeleton facilitated by actin binding 
proteins [1]. Fascin is one of actin cross-linking 
proteins and can participate in forming parallel actin 
bundles in cell protrusions. Fascin-1 is consequently 
involved in cell adhesion, motility, and signaling. In 
cultured cells, over-expression of fascin-1 can increase 
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Abstract  
Invasion and metastasis are major reason for poor prognosis of digestive system carcinoma patients. Motility and 
migratory capacity are important in contributing to tumor cells’ invasion and metastasis. Fascin is one of actin 
cross-linking proteins and can participate in forming parallel actin bundles in cell protrusions. Fascin-1 is 
consequently involved in cell adhesion, motility, and signaling. In cultured cells, over-expression of fascin-1 can 
increase migration and invasion capacity of cells. Many studies show up-expressions of fascin-1 are significantly 
associated with worse prognosis, poor differentiation, TNM stage, positive for lymph node metastasis, and 
positive for distant metastasis in digestive system carcinoma patients. So fascin-1 may have prognostic value as 
an early biomarker for more aggressive digestive system carcinoma. This review provides detailed account of 
preclinical studies conducted to determine the utility of fascin-1 as a therapeutic and predictive agent in invasion 
and metastasis of carcinomas. 
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migration and invasion capacity of cells [2, 3]. 
Fascin-1 is often expressed in normal mesenchymal, 
endothelial, dendritic and neuronal cells, but not in 
normal epithelia cells [4]. In contrast, increased 
fascin-1 protein has been detected in a variety of 
carcinomas, including lung [5], bladder [6], breast [7], 
esophageal [8], pancreatic [9], colon [1], ovary [10]and 
stomach [11]cancer. Furthermore, studies also found 
high expression of fascin-1 protein was often correlated 
with poor prognosis in some carcinomas because it can 
facilitate invasion and metastasis of cancer cells [4, 5]. 
This review provides detailed account of preclinical 
studies conducted to determine the utility of fascin-1 as 
a therapeutic and predictive agent in invasion and 
metastasis of carcinomas. 
Fascin structure and function    
Fascin was discovered in the 1970s as a 55 kDa 
actin-bingding protein that was purified from 
cytoplasmic extracts of sea urchin oocytes or 
coelomocytes [12, 13]. Fascin has been shown to play 
a role in the organizating of actin-based structures that 
regulate adhesion and migration of cell. Three 
fascin-related gene products have been cloned in 
human. Fascin-1, commonly referred to as fascin, 
widely expresses in mesenchymal tissues and nervous 
system; Fascin-2 expresses in retinal photoreceptor 
cells; and fascin-3 is testis specific [2, 3]. Human 
fascin-1 gene, FSCN1, is located at chromosome 7q22 
[14]. Fascin-1 belongs to the β-trefoil group of 
proteins and is predicted to be composed of four 
β-trefoil domains by structural alignment [15]. The 
most highly conserved region is between residues 11 
and 50 in all fascins and these regions contain a 
consensus motif for phosphorylation by protein kinase 
C (PKC) that is present in all fascins. Expression and 
subcellular localization of fascin-1 in cultured cells 
have been studied primarily with vertebrate fascin-1 
and fascin-1 is not uniformly expressed in different 
cell types. It presents to be low or absent in T cells and 
several epithelial cell lines, but expresses at high 
levels in neurons, glial cells, skeletal and smooth 
muscle cells, endothelial cells and some epithelial 
tumour cells [16-19]. By studies of actively migrating 
cultured cells, fascin functions in cell protrusions have 
been reinforced, where fascin-1 localizes in 
microspikes and ruffles at the leading edges of motile 
and post-mitotic cells [18, 20-22]. The role of fascin-1 
in cell migration has been investigated by direct 
perturbation of the actin-binding domains of fascin-1. 
Fascin-1 has also been linked to the organization of 
cell-cell adhesive contacts. In fascin-positive epithelial 
tumour lines fascin-1 localizes at cell-cell adherens 
junctions [23]. Over-expression of fascin-1 in 
epithelial cells correlates with disorganization of 
adherens junctions and reduced cell-cell attachment 
activity [20, 23, 24]. The mechanism of these effects is 
believed to involve an interaction between fascin-1 
and β-catenin that could affect the function of 
β-catenin in cadherin- and occluding-dependent 
adhesion complexes [23, 24].   
Fascin-1 and Carcinoma of Digestive 
System, and Fascin-1 and Oral Squamous 
Cell Carcinoma 
Oral squamous cell carcinoma (OSCC) is one of the 
most common head and neck cancers and is associated 
with a high potential of tumor recurrence and 
metastasis, leading to poor prognosis. 
Down-regulation of fascin-1 protein by using siRNA 
directly led to changes of cell surface protrusions and 
resulted in suppression of migration, invasion and 
increase of adhesion in OSCC and down-regulation of 
fascin-1 expression also resulted in alterations of 
E-cadherin, beta-catenin and Twist at certain level, 
implicative of an association with 
epithelial-mesenchymal transition (EMT). These 
results suggested that expression of fascin-1 protein 
may play an essential role in regulation of progression 
of OSCC and contributes to the event of EMT in the 
early aggressiveness of OSCC [25]. Further, fascin-1 
over-expression was found in OSCC clinical samples 
and its expression was significantly associated with 
nodal metastasis, tumor recurrence and poor patients’ 
overall survival. Consistently, fascin-1 proteins were 
detected in OSCC cell lines with the expression level 
corresponding to the invasion ability. Over-expression 
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of fascin-1 might enhance OSCC aggressiveness by 
interacting with E-cadherin because fascin-1 was 
negatively correlated with E-cadherin expression [26].  
Fascin-1 and Esophageal Squamous Cell 
Carcinoma   
In esophageal squamous cell carcinoma (ESCC), the 
intensity of fascin-1 expression was usually increased 
in the carcinoma compared with that in normal 
epithelium. Over-expression of fascin-1 was 
significantly associated with a poor prognosis, extent 
of the tumor and lymph node metastasis. Multivariate 
analysis showed that fascin-1 expression intensity was 
an independent prognostic factor [8]. Univariate 
survival analysis showed high scores of fascin-1 are 
significantly associated with worse prognosis, poor 
differentiation, T4 stage, positive for lymph node 
metastasis, and positive for distant metastasis in 
patients [27]. In addition, up-regulation of fascin-1 
mRNA was found in 60% of patients and in vitro 
study revealed that KYSE170, one of the 
over-expressed fascin-1 cells, decreased its motile and 
invasive properties after down-regulation of fascin-1 
expression [28]. The effect of fascin-1 on cell 
invasiveness correlated with the activation of matrix 
metalloproteases (MMP) such as MMP-2 and MMP-9. 
These results suggested that fascin-1 might play 
crucial roles in regulating neoplasm progression of 
ESCC [29]. Down-regulation of fascin-1 by using 
RNA interference (RNAi) resulted in a suppression of 
cell proliferation and as well as a decrease in cell 
invasiveness [29, 30].  Forced expression of fascin-1 
in immortalized esophageal epithelial cells accelerated 
cell proliferation and invasiveness. Expression of 
either CYR61 or CTGF led to a recovery of the 
suppression of cellular proliferation and invasiveness 
induced by down-regulation of fascin-1 expression; 
the protein level of CYR61 and CTGF were 
up-regulated in ESCCs and their expression pattern 
correlated with fascin-1 overexpression. Fascin-1 
affected the expressions of CYR61 and CTGF through 
transforming growth factor (TGF)-beta pathway [30]. 
In ESCC transcription factor Sp1 can regulate 
expression of fascin-1 through binding FSCN1 
promoter. Fascin-1 expression is enhanced by Sp1 
over-expression and blocked by Sp1 RNAi 
knockdown. Specific inhibition of ERK1/2 decreased 
phosphorylation levels of Sp1, and thus suppressed the 
transcription of the FSCN1, resulting in the 
down-regulation of fascin-1. Stimulation with EGF 
could enhance fascin-1 expression via activating the 
ERK1/2 pathway and increasing phosphorylation 
levels of Sp1 [31]. 
Fascin-1 and Gastric Carcinoma  
Gastric carcinoma is one of the most common 
digestive malignancies in the world and lymph node 
metastasis is a major prognostic factor in gastric 
carcinomas. Malignant gastric tissues expressed high 
levels of fascin-1 compared with normal gastric tissues 
[32]. By immunohistochemistry, increased fascin-1 
was found in gastric carcinoma and adenoma than in 
adjacent non-neoplastic mucosa. Among the poorly 
differentiated gastric adenocarcinomas, it exhibited 
moderate or strong fascin-1 expression [11]. Most of 
the gastric carcinoma cell lines showed expression of 
fascin-1 at different levels. Silencing of fascin-1 
resulted in altered cancer cell morphology, decreased 
cell motility, and reduced malignant cell invasion [32]. 
Univariate analysis indicated the cumulative survival 
rate of patients with positive fascin-1 expression to be 
lower than without its expression even stratified 
according to the depth of invasion [33]. Some previous 
studies also showed fascin-1 expression was correlated 
with age, serosal invasion, positive lymph node 
metastasis, histopathological grading, TNM stage and 
recurrence and those with fascin-positive tumors had a 
significantly poorer prognosis than those with 
fascin-negative tumors [11, 34]. Other study also 
showed that high expression of fascin-1 protein was 
observed in gastrointestinal stromal tumor and fascin-1 
over-expression was significantly correlated with 
shorter disease-free survival time and several 
aggressive pathological factors, including tumor size, 
mitotic counts, risk grade, blood vessel invasion and 
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mucosal ulceration. Fascin-1 might be a direct target 
of miR-133b and down-regulation of miR-133b made 
the expression of fascin-1 increase in gastrointestinal 
stromal tumor [35].  
Fascin-1 and Colon Carcinoma  
Fascin-1 was not expressed by the normal colonic 
epithelium. In the clinically-annotated tumors, fascin-1 
immunoreactivity was more common in tumors 
located in the proximal colon [36]. For both central 
tumor tissue and the invasive front, it was found that 
the percentage of stained cells was a sufficient 
measure of fascin-1 expression [37]. Fascin-1 was 
exclusively localized at the invasive front of tumors 
also displaying nuclear beta-catenin. Forced 
expression of fascin-1 in colorectal cancer cells 
increased their migration and invasion in cell cultures 
and caused cell dissemination and metastasis in vivo, 
whereas suppression of fascin-1 expression by small 
interfering RNA reduces cell invasion. Although 
expression of fascin-1 in primary tumors correlated 
with the presence of metastases, fascin-1 was not 
expressed in metastases. Moreover, the expression of 
fascin-1 is down-regulated when tumor cells reach 
their metastatic destination where migration ceases 
and proliferation is enhanced [38]. Clinical research 
showed there was a significant independent 
association between high fascin-1 expression and 
diminished survival [37]. Patients with stage III/IV 
adenocarcinomas with strong fascin-1 
immunoreactivity had a worse prognosis than patients 
with low or absent fascin-1. Strong and diffuse 
expression was seen in a subset of advanced colorectal 
adenocarcinomas that correlated with shorter survival 
in stage III and IV patients [36]. Other research also 
showed that five-year survival rate was significantly 
low, whereas the distant recurrence rate was 
significantly high in patients with fascin-positive stage 
III colorectal cancer and there was no significant 
correlation between fascin-1 expression and 
clinicopathologic factors such as tumor size, nodal 
metastasis, pathologic stage. Fascin-1 expression was 
an independent prognostic factor in multivariate 
analysis [39]. So fascin-1 may have prognostic value 
as an early biomarker for more aggressive colorectal 
adenocarcinomas.  
Fascin-1 and Hepatocellular Carcinoma   
Using immunohistochemically, Iguchi T et al. showed 
in patients with hepatocellular carcinoma (HCC), 
tumors showing fascin-1 expression were larger and 
less differentiated than those showing no fascin-1 
expression. Our research also showed hepatocellular 
carcinoma tissues expressed high levels of fascin-1 
compared with adjacent non-cancerous hepatic tissues 
(Fig.1). Portal venous invasion, bile duct invasion, and 
intrahepatic metastasis were detected significantly 
more frequently in fascin-positive group. In addition, 
high alpha-fetoprotein (AFP) levels were significantly 
associated with the fascin-1 expression in HCC. 
Fascin-positive patients had significantly poorer 
outcomes than fascin-negative group and Fascin-1 can 
be as an independent prognostic factor for disease-free 
survival [40]. One mechanism may be that fascin-1 
was involved in EMT and increases invasiveness, thus 
serving as a promoter of cancer aggressiveness. 
Immunohistochemical analysis revealed that fascin-1 
expression in 19% of primary HCCs was associated 
with repression of E-cadherin expression, indicating 
EMT. In vitro, HLE cells showed high fascin-1 
expression, loss of E-cadherin, and efficient invasion 
through matrigel. Knockdown of fascin-1 significantly 
repressed invasiveness of the HLE cells and slightly 
induced E-cadherin expression. In contrast, Huh7 cells 
had low fascin-1 levels, high E-cadherin expression, 
and were expectedly non-invasive. However, forced 
overexpression of fascin-1 conferred only modest 
invasiveness without E-cadherin repression, indicating 
that fascin-1 alone cannot effectively stimulate 
invasiveness or EMT. Fascin-1 overexpression 
dramatically increased the migratory potential of Huh7 
cells. Other mechanism may be that MMP 2 and 9 was 
involved in this process. Significant MMP secretion 
was only found in HLE cells. Although MMP levels 
were not elevated in fascin-1-overexpressing Huh7 
cells, their invasiveness was remarkably augmented by 
coculture with HLE cells, and was suppressed in the 
presence of an MMP inhibitor. In conclusion, it 
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proposed that fascin-1 primarily acts as a migration 
factor associated with EMT in HCC cells and 
facilitates their invasiveness in combination with 
MMPs [41]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figue 1 The expression of fascin-1 protein in HCC and adjacent non-cancerous hepatic tissues. (A) Adjacent non-cancerous 
hepatic tissues, (B) HCC tissues 
 
Fascin-1 and Biliary Tract Carcinoma   
Fascin-1 expression was absent or sporadic in normal 
biliary epithelium, whereas high expression was found 
in dysplasias and intrahepatic biliary tract carcinoma 
[42]. Fascin-1 localized to the cytoplasm and 
membrane compartment of the carcinomas of the 
biliary tract. Fascin-1 is up-regulated during 
progression from in situ to infiltrating gallbladder and 
biliary tract carcinoma [43]. High expression of 
fascin-1 was correlated with poorly differentiated 
tumors and among poorly differentiated intrahepatic 
cholangiocarcinoma, larger tumors (>5 cm) were more 
likely than smaller lesions to have high fascin-1 
expression. Patients whose tumors expressed fascin-1 
abundantly had a poorer outcome, and fascin-1 
over-expression was an independent prognostic factor 
[42]. 
Fascin-1 and Pancreas Carcinoma  
Through evaluating fascin-1 expression in surgical 
specimens, Yamaguchi H et al. found fascin-1 
expression was significantly higher in borderline 
neoplasms and carcinomas than in adenomas, but no 
difference was observed between borderline neoplasms 
and carcinomas. With regard to the subclassification, 
intestinal-type neoplasms were more frequently 
positive for fascin-1 than gastric-type neoplasms. Two 
oncocytic-type neoplasms were both fascin-negative. 
Fascin-1 mRNA expression seemed to be higher in 
moderately to severely dysplastic epithelium than in 
mildly dysplastic epithelium [44]. Other study also 
indicated overexpression of fascin-1 was restricted to 
the cytoplasm and membrane of carcinoma of the 
epithelial cells. Fascin-1 showed up-regulation of 
expression with transition from carcinoma in situ to 
invasive carcinoma, implicating a role for these 
markers in neoplastic progression [43]. 
Conclusions  
Fascin-1 exhibited important roles in an expanding 
area of cytoskeletal and cell biology researchs. 
Growing knowledge of the roles of fascin-1 in human 
carcinoma focuses attention on their possible value as 
therapeutic targets. During the last ten years, fascin-1 
has emerged as a novel biomarker with general 
applicability to aggressive carcinomas from digestive 
system. With the identification of migrastatin as a 
tumour-suppressive small molecule inhibitor of actin 
bundling by fascin-1, interest in the regulation of 
fascin-1 as a candidate target in tumour metastasis is 
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poised to grow over the next years. 
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